Heterozygous Familial Hypercholesterolemia Management

Patients (aged 18–80 years) diagnosed with definite or possible HeFH by Simon Broome criteria [16 (link)] with a screening fasting LDL-C level of ≥1.8 mmol/L (with a history of arteriosclerotic cardiovascular diseases) or ≥2.6 mmol/L (without a history of arteriosclerotic cardiovascular diseases) and on a stable lipid-lowering therapy (moderate or high intensity statins except for statin intolerance, with or without ezetimibe, niacin, omega-fatty acids) for at least 4 weeks before randomization were eligible. The full inclusion and exclusion criteria are listed in Additional file 1. During the study, participants should remain on the stable dose of moderate or high intensity statins (except for those intolerant for statins) with or without ezetimibe.